Dr. Reddy's Lab launches Tobramycin Inhalation Solution in US market

25 Jun 2019 Evaluate

Dr. Reddy's Laboratories has launched Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the US Food and Drug Administration (USFDA).

According to IQVIA Health, the TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019. The company’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1251.00 -2.60 (-0.21%)
02-Jan-2026 12:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1727.15
Dr. Reddys Lab 1251.00
Cipla 1509.95
Zydus Lifesciences 916.90
Lupin 2108.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×